Comparative Pharmacology
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE PRESERVATIVE FREE versus PYRIDOSTIGMINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE PRESERVATIVE FREE versus PYRIDOSTIGMINE BROMIDE.
EDROPHONIUM CHLORIDE PRESERVATIVE FREE vs PYRIDOSTIGMINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, prolonging the action of acetylcholine at nicotinic and muscarinic receptors, enhancing neuromuscular transmission.
Reversible acetylcholinesterase inhibitor, prolonging the action of acetylcholine at nicotinic and muscarinic receptors.
2 mg intravenous (IV) or intramuscular (IM) as a test dose; for myasthenia gravis diagnosis: 2 mg IV test dose followed by 8 mg IV after 30 seconds if no reaction; for myasthenic crisis: 2 mg IV; for reversal of nondepolarizing neuromuscular blockade: 0.5-1 mg/kg IV.
Oral: 60-120 mg every 3-4 hours (max 360 mg/day). Intravenous: 0.1-0.25 mg/kg IV (max 10 mg per dose) for reversal of nondepolarizing neuromuscular blockade, given with glycopyrrolate or atropine. Intramuscular: 0.2-1 mg for postoperative urinary retention.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours in healthy adults; prolonged up to 4-6 hours in renal impairment.
Terminal half-life: 1-2 hours (prolonged in renal impairment; up to 6 hours in anuria)
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary excretion (10-15%).
Renal: 70-90% unchanged; biliary/fecal: minor (<10%)
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor